## **Core Concept**
The question pertains to the withdrawal of an anti-obesity medication due to psychiatric side effects. This involves understanding the pharmacological properties of various anti-obesity drugs and their potential side effects, particularly those affecting mental health.

## **Why the Correct Answer is Right**
Rimonabant, a cannabinoid receptor type 1 (CB1) antagonist, was used as an anti-obesity drug. It worked by blocking the action of endocannabinoids in the brain, which play a role in regulating appetite and metabolism. However, due to significant psychiatric side effects, including depression and anxiety, rimonabant was withdrawn from the market in many countries. This highlights the importance of considering the mental health impacts of medications.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Orlistat is an anti-obesity drug that works by inhibiting pancreatic lipase, an enzyme that breaks down fats in the intestine. Its side effects primarily involve the gastrointestinal tract, such as oily stools and diarrhea, rather than psychiatric effects.
- **Option B:** Sibutramine was an anti-obesity drug that acted as a noradrenaline and serotonin reuptake inhibitor. While it did have cardiovascular side effects that led to its withdrawal, its primary concerns were not psychiatric side effects like depression or anxiety directly associated with its mechanism.
- **Option C:** There is no commonly recognized anti-obesity drug by this name that fits the context of being withdrawn for psychiatric side effects.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that medications targeting the central nervous system or having significant effects on neurotransmitter systems can have profound psychiatric side effects. Rimonabant's withdrawal serves as a cautionary tale about the importance of rigorous psychiatric side effect monitoring in drug development and post-marketing surveillance.

## **Correct Answer:** . Rimonabant